McMaster researchers and industry partners develop new recommendations to combat ‘superbugs’ in Canada

  22 February 2022

A new proposal developed by an interdisciplinary team of McMaster University researchers calls upon Canadian public health officials to make necessary changes to how novel antibiotics are approved, procured and accessed in Canada.

Led by Lori Burrows, associate director of the Michael G. DeGroote Institute for Infectious Disease Research (IIDR), this new work is a direct response to the growing threat of antimicrobial resistance (AMR).

AMR occurs when microbes develop ways to protect themselves from the effects of antimicrobial medications, such as antibiotics. These resistant microbes are colloquially known as ‘superbugs.’

Today, several novel antibiotics — drugs with efficacy against these superbugs — have been approved for use in other jurisdictions but remain unavailable to Canadian patients.

Further reading: McMaster University
Author(s): McMaster University
Clean Environment  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed